Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in patients with relapsed platinum sensitive ovarian cancer Trial supported by strong ...

As biopharma innovation becomes increasingly data-driven and autonomous, the integration of Chinese AI- renowned for rapid ...

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

BACKGROUND: Neurodevelopmental and functional impairments are among the most consequential morbidities for survivors of ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Dementia associated with Alzheimer’s disease is a progressive neurodegenerative condition characterized by memory loss, cognitive decline, and impaired daily functioning. The growing aging population ...

Moleculin Biotech, Inc. 40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and ...

Shelton, Connecticut Thursday, July 17, 2025, 18:00 Hrs [IST] ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

This year, the EHA Congress provided us with long-term follow-up of some very interesting study, including the GAIA/CLL13 ...

We appreciate the opportunity to address the comments by Yangfan Cheng and colleagues, and Sebastian Walsh and colleagues regarding our Article on long-term gantenerumab treatment in dominantly ...